Related Experiment Videos
Circulating immune complexes in leukaemias and lymphomas
J Kishore1, R Kumar, V P Choudhry
1Department of Microbiology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow.
Insights
Elevated circulating immune complexes (ClC) indicate active leukemia and lymphoma. Levels decreased with treatment in ALL, but not AML or CML-BC, correlating with disease activity and remission duration.
Area of Science:
- Hematology
- Immunology
- Oncology
Background:
- Circulating immune complexes (ClC) are implicated in various autoimmune and malignant conditions.
- Assessing ClC levels may offer insights into disease activity and treatment response in hematological malignancies.
Purpose of the Study:
- To investigate the role of ClC in patients with leukaemias and lymphomas.
- To correlate ClC levels with disease type, activity, and treatment outcomes.
Main Methods:
- Quantification of ClC in 78 patients with leukaemias and lymphomas using Clq deviation ELISA and PEG assay.
- Analysis of ClC levels at initial presentation, during therapy, and in relation to disease characteristics.
Main Results:
- Significant elevation of ClC was observed in all leukaemias at presentation.
- ALL patients showed decreased ClC with remission, unlike AML and CML-BC.
- Non-Hodgkin's lymphoma exhibited higher ClC than Hodgkin's disease, correlating with B symptoms and disease activity.
- ClC levels varied among ALL subtypes, being highest in null-ALL.
- Longer remission durations were noted in ALL patients with normal ClC levels.
Conclusions:
- ClC levels serve as a potential biomarker for disease activity and treatment response in leukaemias and lymphomas.
- The distinct behavior of ClC in ALL versus other hematological malignancies warrants further investigation.
- Monitoring ClC may aid in predicting remission duration and guiding therapeutic strategies.
Abstract:
Circulating immune complexes (ClC) were estimated in 78 patients of leukaemias and lymphomas by Clq deviation ELISA and PEG assay. In all leukaemias a significant elevation in ClC was seen at the time of first presentation. While in ALL a decrease occurred on therapy as partial or complete remission was achieved, no such fall was seen in AML or CML-BC when treated. ClC levels were much higher in non-Hodgkins lymphoma than in Hodgkins disease and showed a direct correlation with B symptoms and activity of the disease. The ClC levels were highest in null-ALL followed by those in common ALL and T-ALL. The mean duration of remission in patients of ALL without elevation in ClC was much longer than in those with ClC.